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In recent years, therapeutic advances for patients with 
advanced non-small cell lung cancer (NSCLC) have been 
substantially limited to non-squamous histology, while 
the treatment of patients with squamous cell carcinoma 
of the lung remained unchanged during the last ten years. 
Patients with squamous cell carcinoma of the lung are 
neither eligible for treatment with pemetrexed (due to the 
qualitative interaction between its efficacy and histology, 
being the drug more effective in non-squamous tumors), 
nor for the monoclonal anti-vascular endothelial growth 
factor (VEGF) antibody bevacizumab (due to safety 
reasons). Furthermore, in clinical practice, no molecularly 
targeted agents have been specifically successful for patients 
with squamous tumors, because epidermal growth factor 
receptor (EGFR) sensitizing mutations and anaplastic 
lymphoma kinase (ALK) rearrangements, as well as the use 
of the respective inhibitors, are virtually limited to non-
squamous tumours. 
In this context, improvements in the treatment of 
patients with squamous cell carcinoma of the lung 
represent an unmet need, and new drugs are eagerly 
awaited. Overexpression of insulin-like growth factor 1 
receptor (IGF-1R) is detectable in a relevant proportion 
of advanced NSCLCs, particularly in squamous tumors. 
Figitumumab is a fully human monoclonal antibody 
directed against IGF-1R. An initial randomized phase 
II trial showed activity when figitumumab was added to 
carboplatin plus paclitaxel, with efficacy outcomes more 
promising in patients with squamous cell carcinoma of the 
lung (1). Based on these data, a randomized phase III trial 
was subsequently and specifically designed in patients with 
advanced NSCLC with non-adenocarcinoma histology, 
with the primary aim of improving overall survival (2). The 
study randomized 681 patients, but disappointingly it was 
closed early by the independent Data Safety Monitoring 
Committee, due to negative outcome of a planned futility 
analysis, and because of an increased incidence of serious 
adverse events and treatment-related deaths in the group 
of patients assigned to figitumumab. Overall survival 
analysis did not suggest any benefit with the experimental 
drug, and the difference between treatment arms was 
even in the opposite direction: median overall survival was 
8.6 months with figitumumab plus chemotherapy compared 
to 9.8 months with chemotherapy alone (hazard ratio 1.18; 
95% confidence interval, 0.99-1.40; P=0.06). There were 
no significant differences in progression-free survival and 
objective response rate. Patients treated with figitumumab 
had a higher rate of serious adverse events (66% vs. 51%) 
and a higher rate of treatment-related lethal adverse 
events (5% vs. 1%). Furthermore, data from the previous 
randomized phase II trial were re-analyzed by the sponsor 
and revealed that the original analysis was incorrect and that 
the promising results in terms of objective response rate and 
progression-free survival were not confirmed (1). 
In the current therapeutic landscape for patients with 
squamous cell carcinoma of the lung, even a modest 
survival benefit could be judged as a clinical achievement. 
For instance, the addition of necitumumab, a monoclonal 
antibody directed against the EGFR receptor, to first-
line chemotherapy for advanced squamous NSCLC was 
associated with a statistically significant improvement in 
overall survival (3). Similarly, the addition of ramucirumab, 
a monoclonal antibody directed against the VEGF 
receptor, to second-line docetaxel was associated with an 
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improvement in overall survival, with subgroup analyses 
suggesting similar efficacy in patients with squamous 
and non-squamous tumors (4). For both these drugs, a 
prolongation of about one month and half in median overall 
survival was observed. Although the results of these two 
studies may theoretically modify future therapeutic choices, 
it should also not be ignored the recent position paper from 
the American Society of Clinical Oncology (ASCO) that 
invited to “raise the bar” in clinical research, by defining 
clinically meaningful outcomes when designing and 
interpreting results of clinical trials (5). Advanced squamous 
NSCLC was chosen as one of the settings discussed by 
the panel: in these patients, considering a median overall 
survival of 10 months achievable with current standard 
treatment, the experts recommended to target at least a 
2.5-3 months’ improvement in median overall survival, 
corresponding to hazard ratio ranging around 0.77-0.80. 
Although the magnitude of the benefit suggested by the 
ASCO working group as clinically meaningful is necessarily 
subjective, smaller benefit, even if reaching the formal 
threshold of statistical significance, could be probably 
judged as clinically not relevant. From this point of view, the 
phase III trial of figitumumab was well designed, because 
sample size was based on the hypothesis of achieving a 30% 
improvement with the addition of figitumumab to paclitaxel 
plus carboplatin, over the median survival of 10 months 
achievable with chemotherapy alone, corresponding to a 
hazard ratio 0.77. If the predicted study hypothesis had been 
reached, the benefit could have been considered clinically 
relevant. Similarly to other studies investigating the role 
of targeted therapies in the setting of advanced NSCLC, 
the figitumumab study did not include any predictive 
biomarker to improve treatment efficacy, even if in the 
study a prospective assessment of several potential markers 
was included. Similarly to what we have observed in recent 
years in adenocarcinoma, also patients with squamous 
tumors would benefit from new drugs clinically investigated 
on the basis of a better knowledge of the relevance of 
the targets, and consequently with a proper selection of 
patients, in order to obtain larger benefits in molecularly 
characterized subgroups. Unfortunately, this was not the 
case for figitumumab: the randomized phase III trial was 
initiated without any robust knowledge about predictive 
factors. Subsequently, interesting pre-clinical data have been 
published about the predictive role for figitumumab activity 
of several components of the IGF pathway, including 
insulin receptor substrate 2 (IRS2) and IGF-binding protein 
5 (IGFBP5), and of the alteration or expression of the MYB 
oncogene (6). These data are probably too late for changing 
the story of figitumumab, because its development has been 
discontinued, but could help to improve the development of 
other IGF-1R inhibitors. 
Interestingly, in the study of figitumumab, baseline 
IGF-1 levels were predictive of figitumumab toxicity: 
patients with low levels of IGF-1 appeared to be at 
higher risk of toxic death when treated with figitumumab. 
However, the practical implication of this finding appears 
limited. Ironically, as a matter of fact, a predictive factor 
of severe toxicity for a drug that did not prove any benefit 
in the whole study population is completely the opposite 
of the ideal scenario that would be a drug well tolerated in 
the whole population, with an optimal biomarker useful to 
select patients who could benefit from the treatment. 
We can derive at least three relevant lessons from the 
negative story of figitumumab development in advanced 
NSCLC. Firstly, clinical results observed with figitumumab 
underline the relevance of randomized phase III trials to 
confirm the efficacy of a drug, especially if the anticipated 
benefit is “incremental”, and not a dramatic improvement 
similar to the effect of targeted drugs in oncogene-addicted 
tumors. Secondly, the story emphasizes the risk of failure in 
the development of a new drug, if the process is conducted 
without any knowledge of predictive factors of its efficacy. 
Thirdly, the development of figitumumab in advanced 
NSCLC tells us that a relevant increase in adverse events 
can be completely missed in phase II trials, which are 
conducted in a limited number of patients. This is a relevant 
finding not to be forgotten, especially in the context of 
the recent wave of approval of new drugs often based on 
the evidence of a strong activity in the early phase trials. 
This could lead to the introduction of new drugs in clinical 
practice with a less solid knowledge of their toxicity profile 
that can necessarily derive only by their use in a wider 
number of patients. 
At the end of the story, after the negative results of the 
phase III trial conducted in first-line, along with the failure 
of another phase III trial conducted in patients with non-
adenocarcinoma NSCLC and testing figitumumab in 
combination with erlotinib (7), the clinical development 
of this anti-IGF-1R antibody in NSCLC has been sadly 
discontinued. Was it the wrong drug for the right target, 
or is the target itself (IGF-1R) not the right driver for the 
biology of squamous lung cancer? Most recently, relevant 
progress has been made in the molecular characterization 
of lung squamous tumors. Interestingly, a comprehensive 
genomic characterization of 178 lung squamous cell 
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carcinomas, conducted as part of The Cancer Genome 
Atlas, showed that this tumor type is characterized by 
complex genomic alterations, but in most cases a potential 
therapeutic target can be identified, offering new issues 
of investigation for the treatment of squamous cell 
lung cancers (8). The hope is that in the next few years, 
many of those potential targets will be addressed by 
specific drugs, reproducing also in squamous tumors the 
meaningful progress recently obtained in patients with lung 
adenocarcinoma. This will probably imply a “fragmentation” 
in many different sub-populations, similarly to what we are 
experiencing in adenocarcinoma, but it will probably help 
to obtain clinically relevant results. 
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